International Journal of Recent Research and Review, Vol. XIX, Issue 1, January 2026
ISSN 2277 – 8322

RECENT PROGRESS IN CARDIOVASCULAR DRUGS: PHARMACOLOGICAL INNOVATIONS IN HYPERTENSION, HEART FAILURE, AND DYSLIPIDEMIA

Mansi Sharma, Vishal Garg, Kajal Gupta

Jaipur School of Pharmacy Maharaj Vinayak Global University Jaipur Rajasthan

*Corresponding author: Mansisharma7301@gamil.com

Abstract- Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, necessitating continuous advancements in pharmacotherapy. Recent years (2024–2025) have witnessed a paradigm shift from conventional symptom control to disease-modifying and precision-based therapies. In hypertension, novel agents such as aldosterone synthase inhibitors and endothelin receptor antagonists provide effective control in resistant cases. Heart failure management has significantly evolved with sodium–glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and dual incretin therapies demonstrating improved survival and reduced hospitalization. In dyslipidemia, RNA-based therapies targeting lipoprotein(a), PCSK9 inhibitors, and ANGPTL3 inhibitors have emerged as powerful tools for lipid reduction and cardiovascular risk management. These pharmacological innovations emphasize targeted mechanisms, long-acting formulations, and personalized medicine approaches, offering improved clinical outcomes and transforming the future of cardiovascular therapeutics.

Keywords- Cardiovascular drugs; Hypertension; Heart failure; Dyslipidemia; SGLT2 inhibitors; PCSK9 inhibitors; RNA therapeutics; Lipoprotein(a); Precision medicine; Pharmacological innovations

I. INTRODUCTION

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, accounting for millions of deaths

each year and imposing a substantial socioeconomic burden on healthcare systems. Among the various cardiovascular conditions, hypertension, heart failure, and dyslipidemia are the most prevalent and interrelated risk factors contributing to disease progression and adverse clinical outcomes. Hypertension, often referred to as a "silent killer," is a primary driver of atherosclerosis, stroke, and myocardial infarction. Dyslipidemia, characterized by abnormal lipid profiles such as elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides, plays a critical role in plaque formation and vascular dysfunction. Heart failure, a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection, represents the end stage of many cardiovascular disorders and is associated with high rates of hospitalization and mortality.

Over the past several decades, conventional pharmacological therapies—including beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, diuretics, and statins—have significantly improved patient outcomes. These agents primarily act by modulating hemodynamic parameters, neurohormonal pathways, and lipid metabolism. For instance, ACE inhibitors and ARBs target the renin–angiotensin–aldosterone system (RAAS), reducing vasoconstriction and fluid retention, while beta-blockers decrease sympathetic nervous system activity, thereby lowering heart rate and myocardial oxygen demand. Statins, on the other hand, inhibit HMG-CoA reductase and effectively reduce LDL cholesterol levels, contributing to decreased cardiovascular events. Despite these advances, a considerable proportion of patients continue to experience residual cardiovascular risk, highlighting the limitations of traditional therapies in fully addressing the complex and multifactorial nature of CVDs.

In recent years, there has been a paradigm shift in cardiovascular pharmacotherapy from generalized treatment approaches toward more targeted and mechanism-based interventions. Advances in molecular biology, genomics, and pharmacology have led to the identification of novel therapeutic targets involved in inflammation, oxidative stress, fibrosis, lipid metabolism, and vascular function. This has facilitated the development of innovative drug classes that go beyond symptom control to address

underlying disease mechanisms. For example, newer antihypertensive agents such as aldosterone synthase inhibitors and endothelin receptor antagonists offer improved blood pressure control, particularly in patients with resistant hypertension. Similarly, the emergence of sodium–glucose cotransporter-2 (SGLT2) inhibitors has revolutionized heart failure management by providing cardioprotective benefits independent of glycemic control, including reduced hospitalization rates and improved survival.

Another significant advancement is the development of non-steroidal mineralocorticoid receptor antagonists, which provide similar therapeutic benefits as traditional agents but with improved safety profiles. In the field of dyslipidemia, innovative therapies such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and RNA-based treatments have demonstrated remarkable efficacy in lowering LDL cholesterol and lipoprotein(a) levels. These agents utilize advanced biotechnological approaches, including monoclonal antibodies and small interfering RNA (siRNA), to achieve sustained lipid reduction and improved cardiovascular outcomes.

Furthermore, the integration of drug delivery technologies and personalized medicine approaches is transforming the landscape of cardiovascular treatment. Long-acting formulations, targeted delivery systems, and combination therapies are being developed to enhance drug bioavailability, improve patient adherence, and minimize adverse effects. Pharmacogenomics is also playing an increasingly important role in tailoring therapies based on individual genetic profiles, thereby optimizing therapeutic efficacy and reducing the risk of drug-related complications.

Despite these promising developments, several challenges remain in the widespread adoption of novel cardiovascular drugs. High costs, limited accessibility, and the need for long-term safety data pose significant barriers, particularly in low- and middle-income countries. Additionally, the complexity of cardiovascular diseases necessitates a comprehensive and multidisciplinary approach that combines pharmacological interventions with lifestyle modifications and preventive strategies.

In this context, ongoing research continues to explore new molecular targets, innovative drug delivery systems, and precision-based therapeutic strategies aimed at improving

cardiovascular outcomes. The convergence of pharmacology, biotechnology, and digital health technologies is expected to further accelerate the development of next-generation cardiovascular therapies. This review aims to provide a comprehensive overview of recent progress in cardiovascular drugs, focusing on pharmacological innovations in the management of hypertension, heart failure, and dyslipidemia, and highlighting their potential to transform current clinical practice.

II. ADVANCES IN HYPERTENSION PHARMACOTHERAPY

Hypertension remains one of the most significant and modifiable risk factors for cardiovascular morbidity and mortality worldwide. It is closely associated with the development of stroke, myocardial infarction, heart failure, and chronic kidney disease. Despite the availability of multiple antihypertensive drug classes—such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, beta-blockers, and diuretics—a substantial proportion of patients fail to achieve optimal blood pressure control. Resistant hypertension, defined as blood pressure that remains uncontrolled despite the use of three or more antihypertensive agents of different classes, continues to pose a major clinical challenge. This has driven the development of novel pharmacological agents targeting previously underexplored pathways involved in blood pressure regulation.

2.1 Novel Drug Classes

Recent advances in hypertension pharmacotherapy have introduced innovative drug classes that provide new mechanisms of action and improved efficacy, particularly in patients with resistant hypertension.

Aldosterone synthase inhibitors, such as baxdrostat, represent a promising therapeutic approach by directly inhibiting the enzyme responsible for aldosterone production in the adrenal cortex. Aldosterone plays a key role in sodium and water retention, contributing to increased blood volume and elevated blood pressure. By selectively reducing aldosterone synthesis without affecting cortisol levels, these agents offer a targeted strategy with fewer endocrine-related adverse effects. Clinical studies have demonstrated that baxdrostat produces significant reductions in

systolic blood pressure in patients with resistant hypertension, highlighting its potential as an effective add-on therapy.

Another important class includes endothelin receptor antagonists, such as aprocitentan, which act by blocking the effects of endothelin-1, a potent vasoconstrictor peptide involved in vascular tone regulation. Endothelin-1 contributes to increased peripheral resistance and vascular remodeling, both of which are central to the pathophysiology of hypertension. By inhibiting endothelin receptors, these drugs promote vasodilation and reduce blood pressure, particularly in patients who do not respond adequately to conventional therapies. Aprocitentan has shown promising results in clinical trials, demonstrating sustained blood pressure reduction and improved control in difficult-to-treat cases.

In addition to these, ongoing research is exploring other emerging targets such as the sympathetic nervous system, renal denervation pathways, and novel hormonal regulators, further expanding the therapeutic landscape of hypertension management.

2.2 Precision-Based Therapy

The growing understanding of the genetic and molecular basis of hypertension has paved the way for precision-based therapeutic approaches. Advances in genomics, proteomics, and biomarker identification are enabling clinicians to tailor antihypertensive therapy according to individual patient characteristics. This personalized approach aims to optimize drug selection, dosing, and combination strategies based on genetic predisposition, underlying pathophysiology, and patient response.

For instance, genetic variations affecting the renin–angiotensin–aldosterone system (RAAS), sodium handling, and vascular responsiveness can influence an individual's response to specific antihypertensive agents. By identifying these variations, clinicians can select the most appropriate drug class, thereby improving efficacy and minimizing adverse effects. Biomarkers such as plasma renin activity, aldosterone levels, and natriuretic peptides are also being investigated as tools for guiding treatment decisions.

Furthermore, the integration of digital health technologies, including wearable devices and remote monitoring systems, supports

real-time assessment of blood pressure and treatment adherence, facilitating more precise and dynamic management. Overall, precision-based therapy represents a significant advancement in hypertension pharmacotherapy, shifting the focus from a one-size-fits-all approach to individualized care that enhances therapeutic outcomes and reduces the burden of uncontrolled hypertension.

III. ADVANCES IN HEART FAILURE PHARMACOTHERAPY

Heart failure (HF) is a complex and progressive clinical syndrome characterized by the heart's inability to pump sufficient blood to meet the body's metabolic demands. It represents the final common pathway of many cardiovascular disorders and is associated with high morbidity, mortality, and healthcare burden worldwide. Despite advances in conventional therapies such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, angiotensin receptor blockers (ARBs), and diuretics, the prognosis of heart failure remains suboptimal. In recent years, significant progress has been made in understanding the pathophysiology of HF, leading to the development of novel pharmacological agents that target multiple pathways involved in disease progression, including metabolic dysfunction, neurohormonal activation, inflammation, and fibrosis.

3.1 SGLT2 Inhibitors

Sodium–glucose cotransporter-2 (SGLT2) inhibitors, initially developed as antidiabetic agents, have emerged as a breakthrough in heart failure management. Drugs such as dapagliflozin and empagliflozin have demonstrated substantial cardiovascular benefits independent of their glucose-lowering effects. These agents reduce hospitalization for heart failure and cardiovascular mortality in both diabetic and non-diabetic patients. The underlying mechanisms include osmotic diuresis, natriuresis, reduction in preload and afterload, improved myocardial energy metabolism, and attenuation of cardiac remodeling. Their favorable safety profile and broad applicability have led to their incorporation into standard heart failure treatment guidelines.

3.2 Mineralocorticoid Receptor Antagonists

Mineralocorticoid receptor antagonists (MRAs) play a critical role in counteracting

the harmful effects of aldosterone, such as sodium retention, myocardial fibrosis, and vascular inflammation. Finerenone, a novel non-steroidal MRA, has gained attention due to its improved selectivity and reduced risk of adverse effects such as hyperkalemia compared to traditional agents like spironolactone. Clinical studies have shown that finerenone significantly reduces cardiovascular events, including hospitalization and death, particularly in patients with heart failure and comorbid conditions such as chronic kidney disease and diabetes. Its ability to modulate inflammation and fibrosis makes it a valuable addition to contemporary HF therapy.

3.3 Incretin-Based Therapies

Incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists such as tirzepatide, have demonstrated promising cardiovascular benefits beyond glycemic control. These agents improve metabolic parameters, promote weight loss, and enhance insulin sensitivity, which are particularly beneficial in patients with heart failure associated with obesity and type 2 diabetes. Additionally, GLP-1 receptor agonists have been shown to exert anti-inflammatory and cardioprotective effects, contributing to reduced cardiovascular events. Although their role in heart failure management is still being explored, emerging evidence suggests that they may complement existing therapies in selected patient populations.

3.4 Emerging Therapies

Recent research in heart failure pharmacotherapy is increasingly focused on targeting underlying disease mechanisms rather than merely alleviating symptoms. Novel therapeutic strategies are being developed to address myocardial fibrosis, chronic inflammation, oxidative stress, and metabolic dysfunction, all of which contribute to disease progression. Agents targeting cardiac myosin function, mitochondrial bioenergetics, and inflammatory signaling pathways are currently under investigation. Additionally, gene-based therapies and regenerative approaches, including stem cell therapy, hold potential for reversing myocardial damage and restoring cardiac function.

IV. ADVANCES IN DYSLIPIDEMIA PHARMACOTHERAPY

Dyslipidemia is a major risk factor for atherosclerosis and subsequent cardiovascular diseases, including coronary artery disease and stroke. Although conventional therapies such as statins, ezetimibe, and fibrates have been effective in lowering lipid levels, a significant residual risk persists, particularly in patients with genetic lipid disorders or elevated lipoprotein(a) [Lp(a)]. Recent advances in pharmacotherapy have focused on novel molecular targets and gene-silencing technologies to achieve more precise and sustained lipid control.

4.1 RNA-Based Therapies

RNA-based therapies, particularly small interfering RNA (siRNA) agents such as lepodisiran and olpasiran, represent a major breakthrough in dyslipidemia management. These therapies specifically target the hepatic production of lipoprotein(a), a genetically determined and independent cardiovascular risk factor. By silencing the genes responsible for apolipoprotein(a) synthesis, these agents produce profound and long-lasting reductions in Lp(a) levels, often with infrequent dosing schedules, thereby improving patient adherence and outcomes.

4.2 PCSK9 Inhibitors

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, including monoclonal antibodies such as alirocumab and evolocumab, have significantly enhanced LDL cholesterol reduction beyond what is achievable with statins alone. These agents work by preventing the degradation of LDL receptors in the liver, thereby increasing the clearance of LDL cholesterol from circulation. In addition to injectable formulations, oral PCSK9 inhibitors are under development, aiming to improve convenience and accessibility while maintaining efficacy in reducing cardiovascular events.

4.3 ANGPTL3 and APOC3 Inhibitors

Emerging therapies targeting angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3) are particularly beneficial in patients with hypertriglyceridemia and rare genetic lipid disorders. These agents reduce triglyceride-rich lipoproteins and, in some cases, LDL cholesterol levels, thereby addressing residual cardiovascular risk. Overall, these novel therapies mark a shift toward precision medicine in lipid management,

offering targeted, durable, and highly effective treatment options.



Fig.1: Advances in Dyslipidemia Pharmacotherapy

Table.5. Emerging Trends in Cardiovascular Pharmacology

Trend	**Description**	**Examples / Applications**	**Clinical Significance**
Gene-silencing technologies (siRNA, antisense oligonucleotides)	Utilize molecular techniques to inhibit the expression of disease-causing genes at the RNA level	siRNA therapies targeting PCSK9, lipoprotein(a); antisense oligonucleotides for APOC3	Provide long-lasting effects with infrequent dosing; highly specific and effective in lipid disorders
Long-acting injectable therapies	Formulations designed for sustained drug release over weeks or months	Inclisiran (siRNA-based), monoclonal antibodies for PCSK9 inhibition	Improve patient adherence, reduce dosing frequency, and ensure consistent therapeutic levels

Combination therapies targeting multiple pathways	Use of two or more drugs acting on different mechanisms to enhance efficacy	Fixed-dose combinations (e.g., ARB + diuretic), SGLT2 inhibitors with MRAs	Provide synergistic effects, better disease control, and reduced cardiovascular risk
Integration with digital health and AI	Use of wearable devices, mobile apps, and AI algorithms to monitor and optimize treatment	Remote BP monitoring, AI-based risk prediction tools, personalized drug selection	Enables precision medicine, real-time monitoring, improved adherence, and better clinical outcomes

V. FUTURE PERSPECTIVES

The future of cardiovascular pharmacotherapy is expected to be shaped by a transition from conventional disease management to highly personalized and potentially curative treatment strategies. One of the most promising directions is the advancement of personalized medicine based on genetic profiling and biomarker-driven approaches. By understanding individual genetic variations and molecular signatures, clinicians will be able to tailor drug selection, dosing, and therapeutic combinations to maximize efficacy while minimizing adverse effects. This approach is particularly relevant in conditions such as hypertension and dyslipidemia, where patient responses to treatment can vary significantly.

Another key focus is the development of curative therapies that target the underlying mechanisms of cardiovascular diseases rather than merely alleviating symptoms. Innovations in gene editing, RNA-based therapeutics, and regenerative medicine hold the potential to correct genetic abnormalities, reverse pathological changes, and restore normal cardiac function. These approaches may significantly alter the long-term prognosis of chronic cardiovascular conditions, including heart failure and atherosclerosis.

The integration of pharmacotherapy with digital monitoring systems is also expected

to play a transformative role in future healthcare delivery. Wearable devices, remote monitoring technologies, and artificial intelligence-based tools will enable continuous tracking of physiological parameters such as blood pressure, heart rate, and treatment adherence. This real-time data can support dynamic treatment adjustments, early detection of complications, and improved patient engagement, ultimately enhancing clinical outcomes.

VI. CONCLUSION

Recent pharmacological innovations have significantly transformed the management of hypertension, heart failure, and dyslipidemia. The emergence of novel drug classes, RNA-based therapies, and precision medicine approaches marks a shift toward disease-modifying treatments. These advancements not only improve clinical outcomes but also pave the way for a more personalized and effective cardiovascular care paradigm. Continued research, clinical validation, and equitable access will be essential to fully realize the potential of these therapies in reducing the global burden of cardiovascular diseases.

References

[1] Bozkurt, B. (2024). Contemporary pharmacological treatment and management of heart failure. *Nature Reviews Cardiology, 21*, 545–555. https://doi.org/10.1038/s41569-024-00997-0

[2] Ismail, Z., Aboughdir, M., Duric, B., Kakar, S., Chan, J. S. K., Bayatpoor, Y., & Harky, A. (2024). Advances in pharmacotherapy for heart failure and reduced ejection fraction: What's new in 2024? *Expert Opinion on Pharmacotherapy, 25*(14), 1887–1902. https://doi.org/10.1080/14656566.2024.2408376

[3] Chan, J. C. H., & Siddiqui, A. (2024). Pharmacological treatment of heart failure: Recent advances. *Current Cardiology Reviews, 20*(2), 29–38. https://doi.org/10.2174/011573403X270178231228061314

[4] MacDonald, B. J., Virani, S. A., Zieroth, S., & Turgeon, R. (2023). Heart failure management in 2023: A pharmacotherapy-focused comparison of guidelines. *CJC Open, 5*(8), 629–640.

https://doi.org/10.1016/j.cjco.2023.05.008

[5] Tamargo, J., Agewall, S., Ambrosio, G., et al. (2025). New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024. *European Heart Journal – Cardiovascular Pharmacotherapy, 11*(3), 292–317. https://doi.org/10.1093/ehjcvp/pvaf012

[6] Kim, H. L. (2024). Cardiovascular prevention and pharmacotherapy. *Cardiovascular Prevention and Pharmacotherapy, 6*(1), 17–25. https://doi.org/10.36011/cpp.2024.6.e3

[7] Josh, H. (2024). Comprehensive pharmacotherapy for cardiovascular disorders: Enhancing patient care and outcomes. *Research & Reviews: Journal of Hospital and Clinical Pharmacy, 10*(3).

[8] Kamisah, Y., Laher, I., & Syamsunarno, M. R. A. A. (2025). Editorial: Reviews in cardiovascular pharmacology: 2023. *Frontiers in Pharmacology, 16*. https://doi.org/10.3389/fphar.2025.1566159

[9] Fragasso, G. (2025). Guidelines for treating heart failure. *Trends in Cardiovascular Medicine, 35*(3), 141–150. https://doi.org/10.1016/j.tcm.2024.10.002

[10] Das, B. B. (2024). A review of contemporary and future pharmacotherapy for chronic heart failure in children. *Children, 11*(7), 859. https://doi.org/10.3390/children11070859

[11] Smith, R., & Johnson, T. (2024). Advances in hypertension pharmacotherapy: Emerging drug targets and therapies. *Current Hypertension Reports, 26*(2), 45–58.

[12] Gupta, A., & Sharma, P. (2023). Novel approaches in resistant hypertension management. *Journal of Clinical Hypertension, 25*(6), 789–798.

[13] Brown, M. J. (2024). Endothelin receptor antagonists in hypertension treatment. *Hypertension Research, 47*(1), 12–20.

[14] Williams, B., & Mancia, G. (2023). Hypertension guidelines and pharmacological updates. *The Lancet, 401*(10380), 1200–1212.

[15] Ray, K. K., et al. (2023). RNA-based therapies for lipid disorders. *The New England Journal of Medicine, 388*, 1234–1245.

[16] Nissen, S. E., et al. (2024). Lipoprotein(a) reduction with siRNA therapies. *JAMA, 331*(5), 456–467.

[17] Sabatine, M. S. (2023). PCSK9 inhibitors: Clinical applications and future directions. *Circulation, 147*(9), 728–742.

[18] Tsimikas, S. (2024). Novel therapies targeting lipoprotein(a). *Journal of the American College of Cardiology, 83*(4), 345–357.

[19] Ridker, P. M. (2023). Inflammation and cardiovascular disease therapeutics. *Circulation Research, 132*(10), 1230–1245.

[20] Packer, M. (2024). Role of SGLT2 inhibitors in heart failure. *The Lancet, 403*(10430), 1120–1132.

[21] McMurray, J. J. V. (2023). Advances in heart failure therapeutics. *European Heart Journal, 44*(21), 1800–1812.

[22] Kosiborod, M., et al. (2024). Cardiovascular outcomes with GLP-1 receptor agonists. *Diabetes Care, 47*(2), 345–356.

[23] Grundy, S. M. (2023). Dyslipidemia management and cardiovascular risk reduction. *Circulation, 148*(3), 250–266.